CUMULATIVE INDEX 1998

Volume 16

January	EXCISION AND REPAIR, pages 1–217
April	DERMATOLOGIC THERAPY, pages 219–435
July	PEDIATRIC DERMATOLOGY, pages 437–647
October	SEXUALLY TRANSMITTED DISEASES, pages 649–886

Note: Page numbers of article titles are in **boldface** type

A to T/O to T flaps, in excision and repair, 67–68
Acetic acid test, for balanitis, 759
  for human papillomavirus infections, 818
Acitretin, adverse effects of, 336, 425–426
  indications for, 331–333
Acne, isotretinoin for, 333–335
Acrochordons, as markers for spinal dysraphism, 452
Actinic degeneration, PUVA photochemotherapy and, 227–228
Actinic keratoses, prevention of, sunscreens in, 222
Actinic prurigo, in children, 575–576
Actinomycosis, in cervicitis, 743
Acute febrile neutrophilic dermatosis, in children, 602
Acyclovir, for genital herpes, in pregnancy, 807, 808
  for herpes simplex virus infections, 410–411
  in pediatric dermatology, 540, 542, 543, 545, 546
Adult skin disease, in children, **593–608**
    immunobullous diseases, 603–604
    lichen planus, 598–600
      clinical features of, 598–600
      treatment of, 600
    lichen sclerosus, 604–605
    mycosis fungoides, 602–603
    psoriasis, 593–598
      clinical features of, 593–595
      essential fatty acids for, 637
      prognosis for, 598
      treatment of, 564–565, 595–598
    rosacea, 600–602
      clinical features of, 600–601
      treatment of, 601–602
    Sweet's syndrome, 602
Advancement flaps, in excision and repair. See *Flaps.*
  in nasal reconstruction, 98–99, 101
  in scar revision, 191
Agranulocytosis, dapsone and, 423
AIDS, and molluscum contagiosum, 839–841
  future trends in, 650
Alcohol intake, and excision and repair, 8
Alexandrite laser therapy, for pigmented lesions, 256
Alexithymia, in pediatric dermatology, 621
Alginates, in wound dressings, 40–41
Allergic contact dermatitis, and balanitis, 760
Allergies, and excision and repair, 6–7
Alopecia, hair regrowth in. See *Hair regrowth.*
Aluminum chloride, for hyperhidrosis, 864
Amebiasis, and balanitis, 759
  and genital ulcers, 680
Amino acids, sulfur-containing, in dermatologic therapy, 638
δ-Amino-levulinic acid, for cutaneous T-cell lymphoma, 305–306
4-Aminoquinolone-derived antimalarials, adverse effects of, 422
Amniotic fluid, in harlequin ichthyosis, 506
AMPLICOR, to diagnose nongonococcal urethritis, 724–725
Amputation injuries, of nails, 161
Androgen receptor protein inhibitors, in hair regrowth, for androgenetic alopecia, 344
Androgen receptor proteins, in hair regrowth, for androgenetic alopecia, 342
Androgenetic alopecia, hair regrowth in. See *Hair regrowth.*
Anesthesia, in excision and repair, 54–57
    allergy to, 6
    of ears, 110
    of lips, 130–132
    of nail defects, 149–150
  in extramarginal scar excision, 185
  in laser resurfacing, of scars, 193
  in nasal reconstruction, 92–93
  in spot dermabrasion, 192
Angiofibromas, of tuberous sclerosis, laser therapy for, in children, 492
Angiography, of birthmarks, 457
Anogenital warts, human papillomavirus infections and, **829–834**
    treatment of, 830–833
Anthralin, in hair regrowth, for alopecia areata, 351
  in pediatric dermatology, 597
Antiandrogens, in hair regrowth, for androgenetic alopecia, 344
Antibiotic susceptibility tests, for gonorrhea, 715
Antibiotics, allergy to, and excision and repair, 6
  for gonococcal urethritis, resistance to, 736
  for infected or colonized wounds, 373
  in pediatric dermatology, **509–525**
    cephalosporins, 513–516
      for pyogenic skin infections, 520–521

Antibiotics *(Continued)*
macrolides, 516–517
penicillins, 513
quinolones, 520
resistance to, 510–521
by *Staphylococcus aureus*, 510–511
by *Streptococcus pyogenes*, 510
selection of, 509–511
tetracyclines, 517–520
in wound healing, 28–29
prophylactic, in excision and repair, 30–35
Antibody responses, to genital herpes, 790–791
Anticoagulant agents, as contraindication to excision and repair, 7
Antifungal agents, in pediatric dermatology, **527–537**
fluconazole, 532–533
griseofulvin, 528–530
itraconazole, 530–532
terbinafine, 533–535
Antihelical defects, excision and repair of, 122
Antimalarial agents, adverse effects of, 422
in pediatric dermatology, 580, 584
Antiseptics, for infected or colonized wounds, 373–374
in wound healing, 27–28
Antiviral agents, in pediatric dermatology, **539–552**
for herpes simplex virus infections, 539–547
and varicella-zoster infections, 537–540, 542
cytomegalovirus, 546–547
genital herpes, 542–544
herpes labialis, 542
herpes zoster, 546
in pregnancy, 544–545
neonatal, 545
varicella, 545–546
for human papillomavirus infections, 547–549
cidofovir for, 548
imiquimod for, 548
interferons for, 547–548
vaccines for, 548–549
for poxvirus infections, 549
for viral infections due to child abuse, 549–550
Aplasia cutis, as marker for spinal dysraphism, 452
Aquaphor ointment, to control transepidermal water loss, by neonatal skin, 444
Argon pump tunable dye laser therapy, for vascular lesions, 255
Arteriovenous fistulas, diagnostic imaging of, in children, 468
Arteriovenous malformations, diagnostic imaging of, in children, 462, 465, 468
Arthritis, rheumatoid, in children, 587–589
Artificial joints, and excision and repair, 5
Atopic dermatitis, cyclosporine for, 246
essential fatty acids for, 637
interferons for, 390
Auricular composite skin grafts, in nasal reconstruction, 86–87
Autologous epidermal grafts, for vitiligo, 403–404
Autologous melanocyte grafts, for vitiligo, 404–405
Autonomic nervous system dysfunction, herpes simplex virus infections with, 785
Avascular necrosis, systemic corticosteroids and, 281–282
Avulsion, of nail plate, 153–154
Axillary hyperhidrosis, treatment of, 865
Azathioprine. See *Immunosuppressive agents.*
Azidothymidine, for HIV infection, 412–413
Azithromycin, for syphilis, 703–704
in pediatric dermatology, 516–517

Bacitracin, in wound healing, 28, 29
Bacterial diseases, and balanitis, 758–759
Bacterial vaginosis, **769–773**
and pelvic inflammatory disease, 749
diagnosis of, 769–770
etiology of, 770
in cervicitis, 741–742
observational studies on, 771–772
triggers of, 770–771
Balanitis, **757–762**
bacterial, 758–759
classification of, 757
clinical features of, 757–758
cutaneous causes of, 760–762
fungal, 758
in infants, 757
noninfectious causes of, 760
papillomavirus-associated, 821
protozoan, 759
risk factors for, 758
viral, 759
Balneology, in dermatologic therapy, 631–633
Basal cell carcinoma, genital, ulcerated, 682
interferons for, 387–388
radiotherapy for, 316
Bathing, of neonatal skin, 438–439
Behavioral factors, in pediatric dermatology, 623–625
Behçet's disease, and genital ulcers, 681
azathioprine for, 238
interferons for, 389
Biobrane, in wound dressings, 41
Biofeedback, in pediatric dermatology, 622
Biological dressings, in wound healing, 370–371
Biological response modifiers, for cutaneous T-cell lymphoma, 306–309
in hair regrowth, for alopecia areata, 351–352
for androgenetic alopecia, 344–345, 347
Biopsies, before excision and repair, 10–11
of nail folds, 156–157
of nail unit, 151–153
Birth defects, thalidomide and, 424
Birthmarks, as markers for dysraphism, **447–453**
cranial dysraphism, 447–449
cephaloceles, 447–448
dermoid cyst and sinus, 448–449
hemangiomas, 449
nasal gliomas, 448
imaging of, 452
spinal dysraphism, 449–452
acrochordons, tails, and pseudo-tails, 452
capillary malformations, 452
dimples. aplasia cutis, and congenital scars, 452
hemangiomas, 451
hypertrichosis, 451
lipomas, 451
telangiectasis, 451
diagnostic imaging of, **455–488**
blue rubber bleb nevus syndrome, 479, 481
capillary malformations, 468
choice of protocol for, 457
hemangiomas, 457–461
hereditary hemorrhagic telangiectasia, 481–483
Klippel-Trenaunay syndrome, 474–475
lymphatic malformations, 474
Maffucci syndrome, 481
Parkes-Weber syndrome, 481
proteus syndrome, 475, 479
Sturge-Weber syndrome, 483
vascular malformations, 461–483
arteriovenous fistula, 468
arteriovenous malformations, 462, 465

venous malformations, 468–469, 472
Bleomycin, for verrucae, of nails, 162
Bloom's syndrome, in children, 574
Blue rubber bleb nevus syndrome, diagnostic imaging of, in children, 479, 481
Botulinum toxin, for hyperhidrosis, 866
Brachytherapy, for dermatologic malignancies, 314
Breastfeeding, systemic corticosteroids during, 279
Bullous ichthyosis, retinoids for, in children, 560–562

Café-au-lait macules, laser therapy for, in children, 492–493
Calcipotriene, for psoriasis, 232
in pediatric dermatology, 597
Camouflage techniques, in scar revision, 185
Cancer, cyclosporine and, 427
Candida, in balanitis, 758
in vulvodynia, 775–776
in vulvovaginitis. See *Vulvovaginitis.*
Capillary malformations, as markers for spinal dysraphism, 452
diagnostic imaging of, in children, 468
Captia enzyme immunoassay, for syphilis, 694–695, 701
Carbon dioxide laser matricectomy, technique for, 155–156
Carbon dioxide laser therapy, for anogenital warts, 832
for verrucae, of nails, 162
Carbon dioxide laser vermilionectomy. See *Lips.*
Carbon dioxide lasers, in scar revision, 192–193
in skin resurfacing, 254–255, 265–266
Cardiac involvement, by neonatal lupus, 582
Cardiovascular complications, of systemic corticosteroids, 283
Cardiovascular disease, and excision and repair, 5
Cardiovascular syphilis, treatment of, 707
Cataracts, systemic corticosteroids and, 283
Cefaclor, in pediatric dermatology, 515
Cefadroxil, in pediatric dermatology, 513–514
Cefixime, in pediatric dermatology, 515
Cefpodoxime axetil, in pediatric dermatology, 515
Cefprozil, in pediatric dermatology, 514
Ceftriaxone, for syphilis, 703
Cefuroxime axetil, in pediatric dermatology, 514–515
Cellular repair, disorders of, in children, 573–575
Central nervous system complications, of systemic corticosteroids, 283
Cephalexin, in pediatric dermatology, 514, 516
Cephaloceles, birthmarks as markers of, 447–448
Cephalosporins, in pediatric dermatology, 513–516
Cervical cancer, sexually transmitted diseases with, 848–849
Cervical intraepithelial neoplasia, HIV infection with, 854
Cervicitis, 651–652, **739–745**
complications of, 739–740
diagnosis of, 744
etiology of, 740–744
actinomycosis, 743
bacterial vaginosis, 741–742
chlamydial and gonococcal, 741
fungal diseases, 743
genital mycoplasmas, 741
herpes simplex virus, 742
HIV infection, 744
human papillomavirus, 742–743
protozoal and parasitic diseases, 743
tuberculosis and granulomatous infections, 743
treatment of, 744–745
Chancroid, and genital ulcers, 678
Chemical cautery matricectomy, technique for, 156
Chemical peels, advances in, 253–254
Chemotherapy, for cutaneous T-cell lymphoma, 309
plus interferons, for malignant melanoma, 385–387
Chickenpox, in children, 545–546
Child abuse, and viral infections, 549–550
Chlamydia trachomatis, in nongonococcal urethritis, 723–725
in urethritis/cervicitis, 651, 741
Chloral hydrate, in pediatric dermatology, 615
Chlorhexidine gluconate, in cord care, for neonatal skin, 442–443
Chloroquine, adverse effects of, 422
Chlorpromazine, in pediatric dermatology, 615
Chondritis, ear surgery and, 124
Chondrodermatitis nodularis chronica helices, excision and repair of, 111
Chromophore production, disorders of, in children, 572–573
Cidofovir, in pediatric dermatology, 548, 549
Cigarette smoking, and excision and repair, 8
Cirrhosis, methotrexate and, 426
Clarithromycin, in pediatric dermatology, 516–517
Climatotherapy, in dermatologic therapy, 631–633
Clinical psychology, in pediatric dermatology, **619–629**
behavioral and environmental factors, 623–625
compliance issues, 625–627
stress and emotional regulation, 620–623
Clonidine, transdermal delivery of, 292–293
Coal tar, in pediatric dermatology, 597
Cockayne's syndrome, in children, 574
Cold sores, in children, 542
Collagen, in scar revision, 182
Collagen vascular diseases, in children, **579–592**
dermatomyositis, 582–585
juvenile rheumatoid arthritis, 587–589
lupus erythematosus, 579–581
neonatal lupus, 581–582
scleroderma, 585–587
Sjögren's syndrome, 589
Collodion baby, retinoids for, 559–560
Composite skin grafts, in excision and repair. See *Skin grafts.*
in nasal reconstruction, 97
Compression, in scar revision, 184
postsclerotherapy, 204–206
Computed tomography, of birthmarks, 457
Conchal defects, excision and repair of, 122
Congenital bullous ichthyosiform erythroderma, retinoids for, in children, 560–562
Congenital ichthyosiform erythroderma, clinical features of, 504–505
Connective tissue complications, of systemic corticosteroids, 280–282
Contact sensitization therapy, in hair regrowth, for alopecia areata, 350–351
Contraception, in HIV-infected women, 850
Copper, in dermatologic therapy, 638
Cord care, for neonatal skin, 439–443
Cornification, inherited disorders of. See *Inherited disorders of cornification.*
Corticosteroids, for psoriasis, 232
for vitiligo, 401–403
in hair regrowth, for alopecia areata, 349–350
systemic. See *Systemic corticosteroids.*
Cranial dysraphism, birthmarks as markers of. See *Birthmarks.*
Crohn's disease, and genital ulcers, 681
Cryosurgery, for verrucae, of nails, 161–162

Cryosurgery *(Continued)*
in scar revision, 184
Cryotherapy, for anogenital warts, 831
minimizing pain of, in children, 613–614
CSF-VDRL test, for neurosyphilis, 704–705
Cupid's bow, excision and repair of, 134
Cutaneous necrosis, sclerotherapy and, 209–210
Cutaneous T-cell lymphoma, evaluation of, 302–304
pathogenesis of, 301–302
treatment of, **301–311**
acitretin and etretinate in, 333
biological response modifiers in, 306–309
chemotherapy in, 309
combination therapy in, 309
interferons in, 383–385
radiotherapy in, 318–319
skin-directed therapy in, 305–306
Cyclophosphamide. See *Immunosuppressive agents.*
in pediatric dermatology, 587
Cyclosporine. See *Immunosuppressive agents.*
Cyproterone acetate, in hair regrowth, for androgenetic alopecia, 344
Cystitis, hemorrhagic, cyclophosphamide and, 241
Cysts, epidermal inclusion, of ears, excision and repair of, 111–112
Cytomegalovirus infections, in children, 546–547
treatment of, 412

Dacarbazine, plus interferons, for malignant melanoma, 385–387
Dapsone, adverse effects of, 423
Darier's disease, retinoids for, in children, 563–564
Dark ground microscopy, of *Treponema pallidum*, in syphilis, 696–697
Delavirdine, for HIV infection, 414
Dermabrasion, in scar revision, 191–192
Dermal replacements, in wound healing, 371
Dermal sinuses, birthmarks as markers of, 449
Dermatitis, and balanitis, 760
atopic, cyclosporine for, 246
interferons for, 390
perioral, rosacea and, in children, 600–601
Dermatologic therapy, adverse effects of, **421–429**
acitretin and etretinate, 336, 425–426
4-aminoquinolone-derived antimalarials, 422
azathioprine, 237–238
chloroquine, 422
cyclophosphamide, 239, 241
cyclosporine, 245–246, 427
dapsone, 423
hydroxychloroquine, 422
interferons, 390–391
isotretinoin, 336, 424–425
methotrexate, 243–244, 426
minocycline, 422
systemic corticosteroids. See *Systemic corticosteroids.*
systemic retinoids, 335–336
tetracyclines, 421–422
thalidomide, 423–424
extemporaneous compounding in, **321–327**, **329–330**
alternatives to, 325
complications of, 322–325
drug interactions, 323
drug stability, 324
effectiveness of drugs, 322–323
rheology and cosmesis, 324–325
sterility, 323–324
economics of, 325
legal issues in, 325–326
rationale for, 321–322
for cutaneous T-cell lymphoma. See *Cutaneous T-cell lymphoma.*
for melanoma. See *Malignant melanoma.*
for photoaging. See *Photoaging.*
for viral diseases. See *Viral diseases.*
for vitiligo. See *Vitiligo.*
from Europe, **631–641**
diet, 635–638
copper, 638
essential fatty acids, 635–637
iron, 637
selenium, 638
sulfur-containing amino acids, 638
zinc, 637–638
immunology and mineral waters, 632–633
mineral waters and psychoneuropeptidergic system, 633
nocebo effect, 634
physical medicine, 638–639
placebo effect, 633–635
definition of, 633–634
possible explanation for, 635
Ratokderm, 639–640
regime/climatotherapy and balneology, 631–633
immunosuppressive agents in. See *Immunosuppressive agents.*
in hair regrowth. See *Hair regrowth.*
in wound healing. See *Wound healing.*
interferons in. See *Interferons.*
lasers in. See *Lasers.*
PUVA photochemotherapy in. See *PUVA photochemotherapy.*
radiotherapy in. See *Radiotherapy.*
sunscreens in. See *Sunscreens.*
surgical, **253–259**
chemical peels, 253–254
combined resurfacing approaches, 255
hair replacement, 257–258
lasers for hair removal, 256, 266–267
lasers for pigmented lesions, 256, 264–265
lasers for skin resurfacing, 254–255, 265–266
lasers for vascular lesions, 255–256, 264
phlebology, 257
tumescent liposuction, 256–257
systemic corticosteroids in. See *Systemic corticosteroids.*
systemic retinoids in. See *Systemic retinoids.*
transdermal delivery of. See *Transdermal drug delivery.*
Dermatomyositis, in children, 582–585
Dermatoses, and vulvodynia, 775–776
herpes simplex virus infections with, 786
Dermoid cysts, birthmarks as markers of, 448–449
Diabetes mellitus, and excision and repair, 5
herpes simplex virus infections with, 786
Diaper rash products, for neonatal skin, 439
Diapering, of neonatal skin, 439
Didanosine, for HIV infection, 412–413
Diet, in dermatologic therapy. See *Dermatologic therapy.*
Dimples, lumbosacral, as markers for spinal dysraphism, 452
Dinitrochlorobenzene, in hair regrowth, for alopecia areata, 350–351
Diode lasers, advances in, 263–264
Diphenylcyclopropenone, in hair regrowth, for alopecia areata, 350–351
Dirithromycin, in pediatric dermatology, 517
Discoid lupus erythematosus, interferons for, 389
DNA amplification techniques, to diagnose nongonococcal urethritis, 724

to screen for sexually transmitted diseases, 666
Donovanosis, and genital ulcers, 678–679
Dorsonasal flaps, in excision and repair, 71
Doxycycline, for syphilis, 704
Dressings, in excision and repair, **25–47**, 62
alginates in, 40–41
and wound care, 42–43
antibiotic prophylaxis with, 30–35
for endocarditis, 33–35
for wound infections, 31–33
Biobrane in, 41
full-thickness wounds, 27
functions of, 36
growth factors with, 30
hemostatic agents with, 29–30
hydrocolloids in, 39–40
hydrogels in, 40
mechanism of action of, 36
microbiology of, 36–37
N-Terface in, 41
of nail defects, 150–151
partial-thickness wounds, 27
polymer films in, 37–39
polymer foams in, 39
sutured wounds, 27
Telfa-type, 41
topical antibiotics with, 28–29
topical antiseptics with, 27–28
wound healing and, 25–27
granulation, 26
hemostasis, 25
inflammation, 26
wound contraction and tissue remodeling, 26–27
in wound healing, 369–371
Dysraphism, birthmarks as markers of. See *Birthmarks.*

Ears, excision and repair of, **109–125**
anatomy in, 109–110
anesthesia in, 110
complications of, 124
flaps in, 113–117
advancement, 114–116
O to T, 115–116
pedicle, 116–117
rotation, 116
transposition, 116
for antihelical defects, 122
for chondrodermatitis nodularis chronica helices, 111
for conchal defects, 122
for epidermal inclusion cysts, 111–112
for helical rim and auricular defects, 121–122
for helical rim defects, 120–121
for keloids, 111
for lobular defects, 123
for malignant tumors, 112
for nevi, 111
for posterior auricular defects, 123
for tears, 123
for tragal defects, 122–123
Mohs micrographic surgery in, 112–113
skin grafts in, 117, 119
full-thickness, 117, 119
split-thickness, 119
surgical plan in, 110–111
wedge excision, 119–120
wound care in, 123–124
Eczema herpeticum, in children, 544
Electrocurrent, in scar revision, 184
Electrodesiccation and curettage matricectomy, technique for, 155
Electron beam therapy, for dermatologic malignancies, 314
in scar revision, 184
Electrorydesis, in dermatologic therapy, 638–639
Electrosurgery, for anogenital warts, 831–832
for verrucae, of nails, 162
Emollients, for neonatal skin, 439
in pediatric dermatology, 596
Endocarditis, prevention of, antibiotics in, 33–35
Endometritis, in pelvic inflammatory disease, 748–749
Environmental factors, in pediatric dermatology, 623–625
Enzyme-linked immunosorbent assays, of *Neisseria gonorrhoeae*, 715
Epidermal grafts, autologous, for vitiligo, 403–404
Epidermal inclusion cysts, of ears, excision and repair of, 111–112
Epidermal replacements, in wound healing, 371
Epidermodysplasia verruciformis, retinoids for, in children, 566
Epidermolytic hyperkeratosis, clinical features of, 500–502
retinoids for, in children, 560–562
Epilepsy, and excision and repair, 6
Epithelial skin tumors, interferons for, 387–389
Erbium:YAG lasers, in scar revision, 192–193
in skin resurfacing, 255, 266
Erythema multiforme exudativum, and balanitis, 760
Erythroderma, congenital ichthyosiform, 504–505
psoriatic, in children, 595
Erythromycin, in pediatric dermatology, resistance to, 511
Erythropoietic porphyria, in children, 572
Essential fatty acids, in dermatologic therapy, 635–637
Estrogens, in hair regrowth, for androgenetic alopecia, 344
Etretinate, adverse effects of, 425–426
in pediatric dermatology, 557, 559, 561
indications for, 331–333
Eucerin Creme, to control transepidermal water loss, by neonatal skin, 444
Excision and repair, atlas of, **165–178**
closures, 166–175
complications, 176–178
dressings in. See *Dressings.*
flaps in. See *Flaps.*
in nasal reconstruction. See *Nasal reconstruction.*
of ears. See *Ears.*
of lips. See *Lips.*
of nails. See *Nails.*
preoperative evaluation for, **1–15**
consultation area in, 1
for hair transplant, 12
for laser therapy, 12–13
for liposuction, 13
for Mohs micrographic surgery, 13
for sclerotherapy, 13
for skin resurfacing, 13
in children, 13
in elderly, 13
in psychiatric patient, 13–14
informed consent in, 11–12
medical history in, 1–8
allergies, 6–7
existing and past medical problems, 5–6
medications, 7
response to prior procedures, 7

Excision and repair *(Continued)*
social issues, 7–8
physical examination in, 8–11
biopsies, 10–11
laboratory tests, 10
scar revision. See *Scar revision.*
simple, **49–64**
anesthesia in, 54–56
anesthesia injection in, 56–57
closure in, 58–62
buried interrupted dermal sutures in, 60–61
hemostasis in, 59
running subcuticular sutures in, 61–62
simple interrupted percutaneous sutures in, 60
suture material in, 59
undermining in, 58
vertical mattress sutures in, 61
complications of, 62–63
dressings in, 62
ellipse orientation in, 51–54
contour lines and cosmetic units and, 52–53
dimensions in, 53
resting skin tension lines and, 52
variations in, 53–54
incision in, 57
instrumentation for, 54
postoperative care for, 62
preoperative evaluation for, 51
skin marking in, 56
skin preparation for, 56
specimen removal in, 58
surgical anatomy in, 49–51
lymphatics, 51
nerves, 49–51
parotid gland, 51
vasculature, 49
skin grafts in. See *Skin grafts.*
surgical tray in. See *Surgical tray.*
Extracorporeal photochemotherapy, in pediatric dermatology, 585

Factitial ulcerations, genital, 682–683
Famciclovir, for herpes simplex virus infections, 411
in pediatric dermatology, 542, 543, 546
Family environment, in pediatric dermatology, 622
Fat injection, in scar revision, 182
Fatty acids, essential, in dermatologic therapy, 635–637
Fentanyl, in pediatric dermatology, 615–616
transdermal delivery of, 293
Fever blisters, in children, 542
Fibrel, in scar revision, 182
Finasteride, in hair regrowth, for androgenetic alopecia, 343–344
Fixed drug eruptions, and balanitis, 760–761
Flaps, in excision and repair, **65–74**
advancement flaps, 66–69
A to T/O to T, 67–68
double, 67
island pedicle, 68–69
single, 67
of auricular defects, 113–117
rotation flaps, 69–71
dorsonasal, 71
O to Z, 69
single, 69
transposition flaps, 71–74
bi-lobe, 73–74
rhombic, 74
single lobe, 72–73
in hair replacement, 258
in nasal reconstruction. See *Nasal reconstruction.*
in scar revision, 191
Flashlamp pumped pulse dye laser therapy, for vascular lesions, 255
Fluconazole, in pediatric dermatology, 532–533
Fluorescence microscopy, of *Treponema pallidum*, in syphilis, 697
Fluorescent treponemal antibody absorption test, for syphilis, 701
5-Fluorouracil, for anogenital warts, 831
Fractures, of nails, 161
Free cartilage grafts, in excision and repair, 88
Full-thickness excision, of lip defects. See *Lips.*
Full-thickness skin grafts, in excision and repair. See *Skin grafts.*
Full-thickness wounds, healing of, 27
Fungal diseases, and balanitis, 758
in cervicitis, 743

Gardnerella vaginalis, in balanitis, 758
Gastrointestinal complications, of azathioprine, 237
of cyclophosphamide, 241
of methotrexate, 243
of systemic corticosteroids, 282–283
Genital herpes, 652–653, 673–674, 677, **789–793**. See also *Herpes simplex virus infections.*
and balanitis, 759
as risk factor for HIV infection, 790
clinical features of, 799–800
diagnosis of, 789, 800
laboratory tests in, 800–801
in children, 542–544
in pregnancy, **805–810**
antepartum treatment of, 807
classification of, 805–807
incidence of, 805
intrapartum treatment of, 807–809
scope of epidemic, 789
serology in, 790–792
transmission of, **795–797**
subclinical, 796
treatment of, **799–803**
antiviral drugs in, 801
follow-up of, 801–802
unrecognized, 796
implications of, 790
Genital mycoplasmas, in cervicitis, 741
Genital pain syndrome, definition of, 652
in men, **779–782**
clinical features of, 779–780
patient history of, 780
physical examination for, 780–782
Genital ulcers, 651, **673–685**
amebiasis and, 680
Behçet's disease and, 681
chancroid and, 678
Crohn's disease and, 681
factitial, 682–683
granuloma inguinale and, 678–679
herpes simplex virus infections and, 673–674, 677
leishmaniasis and, 679–680
lichen planus and, 681–682
lymphogranuloma venereum and, 679
malignant, 682
syphilis and, 677–678
Genital warts, 653

Gentian violet, in cord care, for neonatal skin, 440
Gingivostomatitis, herpetic, in children, 542
Glabellar rotation flaps, in nasal reconstruction, 98
Glabellar transposition flaps, in nasal reconstruction, 98
Gliomas, nasal, birthmarks as markers of, 448
Glycolic acid, in chemical peels, 253
Glycoprotein G based test, for genital herpes, 791–792
Gonococcal urethritis, treatment of, 736–737
Gonorrhea, 650–651, **713–722**
clinical examination and sampling of, 714
clinical history of, 713–714
diagnosis of, 714–715
partner notification of, 716
population control of, 716–720
biological factors in, 719
international comparisons of, 716–718
health service provision in, 718–719
social factors in, 719–720
tests of cure of, 716
treatment of, 715
epidemiologic, 716
Grafts, autologous epidermal, for vitiligo, 403–404
autologous melanocyte, for vitiligo, 404–405
in hair replacement, 257–258
Granulation, in excision and repair, 26
in wound healing, of auricular defects, 112–113
Granuloma inguinale, and genital ulcers, 678–679
Granulomas, pyogenic, laser therapy for, in children, 492
Granulomatous infections, in cervicitis, 743
Griseofulvin, in pediatric dermatology, 528–530
Group B streptococci, in balanitis, 758
Growth factors, in wound healing, 30, 372
Guillotine injuries, of nails, 161
Guttate psoriasis, in children, 595

Hair collar sign, as marker for cephaloceles, 448
Hair regrowth, **341–356**
for alopecia areata, 349–352
biological response modifiers in, 351–352
future of, 354
immunomodulators in, 349–351
treatment plan for, 352
for androgenetic alopecia, 341–349
androgen receptor proteins in, 342
biological response modifiers in, 344–345, 347
hormone modifiers in, 343–344
in men, 347
in women, 347, 349
steroid-metabolizing enzymes in, 342–343
psychological aspects of, 352
Hair removal, lasers in, 266–267
Hair replacement, advances in, 257–258
Hair transplant, preoperative evaluation for, 12
Hand-foot-and-mouth disease, in children, 549
Harlequin ichthyosis, clinical features of, 505–506
retinoids for, in children, 560
Hatchet flaps, in excision and repair, 71
Helical rim defects, excision and repair of, 120–122
Hemangiomas, in children, birthmarks as markers of, 449, 451
diagnostic imaging of, 457–461
differential diagnosis of, 461
laser therapy for, 491
interferons for, 382
Hematologic complications, of azathioprine, 237
of cyclophosphamide, 239
of methotrexate, 243
Hematomas, ear surgery and, 124
full-thickness skin grafts and, 81
of nails, 159–160
simple excision and repair and, 63
Hemolysis, dapsone and, 423
Hemorrhagic cystitis, cyclophosphamide and, 241
Hemostasis, in excision and repair, 25, 59
Hemostatic agents, in wound healing, 29–30
Hepatic complications, of methotrexate, 426
Hepatitis, and excision and repair, 5
herpes simplex virus infections with, 786
in children, 549
Hereditary hemorrhagic telangiectasia, diagnostic imaging of, in children, 481–483
Herpes simplex virus, in cervicitis, 742
Herpes simplex virus infections, **783–788**. See also *Genital herpes.*
and excision and repair, 6
hidden and covert, 787
HIV infection with, 853–854
in children. See *Antiviral agents.*
in immunocompromised, 783–785
treatment of, 410–412
unusual presentations of, 785–787
vaccines for, **811–816**
attenuated live virus vaccines, 814
DNA vaccines, 813–814
for non-genital infections, 815
goals of, 811–812
inactivated whole virus vaccines, 812
replication-impaired virus vaccines, 814
subunit vaccines, 812–813
vectored vaccines, 814–815
HIV infection, and excision and repair, 5
future trends in, 650
genital herpes as risk factor for, 790
in cervicitis, 744
neurosyphilis with, 706
partner notification techniques for, 671
pelvic inflammatory disease with, 753–754
prevalence of, 655–656
sexually transmitted diseases with, **853–857**
herpes simplex virus infections, 783–785, 853–854
human papillomavirus infections, 854–855
in women, 656, **847–851**
cancer with, 848–849
clinical features of, 849–850
clinical sequelae of, 848
epidemiology of, 847–848, 849
in pregnancy, 850–851
prevention of, 849
syphilis, 678, 694, 699–701, 854
transmission of, 855
treatment of, 412–417
combination therapy in, 416–417
goals in, 415–417
non-nucleoside reverse transcriptase inhibitors in, 413–414
protease inhibitors in, 414–415
Homosexual men, gonorrhea in, 720
Hormone modifiers, in hair regrowth, for androgenetic alopecia, 343–344
Hormone replacement therapy, transdermal delivery of, 293
Human papillomavirus, in cervicitis, 742–743
Human papillomavirus infections, **817–822**
and anogenital warts, 653, **829–834**
treatment of, 830–833
and balanitis, 759
cervicitis and, 739–740

Human papillomavirus infections *(Continued)*
clinical features of, 818, 820–821
in men, 820–821
in women, 820
diagnosis of, 818
epidemiology of, 817–818
HIV infection with, 854–855
in children, 547–549
molecular mechanisms of, **823–827**
functions of gene products, 824–826
structural biology, 823–824
treatment of, 409–410
interferons in, 380–381
vaccines for, **835–838**
development of, 835–836
prophylactic, 836–837
therapeutic, 837
timing of administration, 837–838
Human parvovirus B19 infection, in children, 549
Hydroa vacciniforme, in children, 576
Hydrocolloid dressings, in wound healing, 39–40, 370
Hydrogels, in wound dressings, 40
Hydrogen peroxide, in wound healing, 28
Hydroxychloroquine, adverse effects of, 422
in pediatric dermatology, 580–581
Hypereosinophilic syndrome, interferons for, 389
Hyperhidrosis, etiology of, 863
treatment of, **863–868**
axillary hyperhidrosis, 865
botulinum toxin in, 866
iontophoresis in, 866–867
sympathectomy in, 865–866
systemic, 865
topical, 864
Hyperkeratosis, epidermolytic, clinical features of, 500–502
retinoids for, 560–562
Hyperosmotic solutions, in sclerotherapy, 207
Hyperpigmentation, sclerotherapy and, 208
tetracyclines and, 421–422
Hypersensitivity reactions, to azathioprine, 238
Hypertension, and excision and repair, 5
cyclosporine and, 245, 427
systemic corticosteroids and, 283
Hypertrichosis, as marker for spinal dysraphism, 451

Ichthyoses. See *Inherited disorders of cornification.*
IgM immunoblot assay, for syphilis, 701
Imiquimod, for anogenital warts, 832
in pediatric dermatology, 548
Immunobullous diseases, azathioprine for, 238
in children, 603–604
Immunologic complications, of PUVA photochemotherapy, 229–230
Immunomodulators, in hair regrowth, for alopecia areata, 349–351
Immunophenotyping, in cutaneous T-cell lymphoma, 303
Immunosuppression, due to ultraviolet light, prevention of, sunscreens in, 223–224
Immunosuppressive agents, **235–251**
azathioprine, 235–239
adverse effects of, 237–238
indications for, 238
pharmacology of, 235, 237
usage guidelines for, 238–239
cyclophosphamide, 239, 241–242
adverse effects of, 239, 241
indications for, 241–242
pharmacology of, 239
usage guidelines for, 242
cyclosporine, 245–247
adverse effects of, 245–246, 427
in pediatric dermatology, 584–585, 598
indications for, 246, 331–332
psoriasis, 232
pharmacology of, 245
usage guidelines for, 246–247
methotrexate, 242–245
adverse effects of, 243–244, 426
in pediatric dermatology, 581, 584, 588, 597–598
indications for, 244
psoriasis, 231–232
pharmacology of, 242–243
usage guidelines for, 244–245
Indinavir, for HIV infection, 414–415
Infections, candidal, and vulvodynia, 775–776
granulomatous, in cervicitis, 743
opportunistic, cyclophosphamide and, 241
methotrexate and, 244
systemic corticosteroids and, 282
wound, after simple excision and repair, 63
prevention of, 31–33
Inflammation, in excision and repair, 26
Inherited disorders of cornification, **497–508**
collodion baby, retinoids for, 559–560
congenital ichthyosiform erythroderma, 504–505
epidermolytic hyperkeratosis, 500–502
retinoids for, 560–562
harlequin ichthyosis, 505–506
retinoids for, 560
ichthyosis vulgaris, 497–499
lamellar ichthyosis, 502–504
retinoids for, 557, 559
nonbullous congenital ichthyosiform erythroderma, retinoids for, 559
X-linked recessive ichthyosis, 499–500
Injections, minimizing pain of, in children, 612–613
Interferons, **377–398**
adverse effects of, 390–391
for anogenital warts, 832
for cutaneous diseases, 389–390
for cutaneous T-cell lymphoma, 307, 383–385
for epithelial skin tumors, 387–389
for hemangiomas, 382
for human papillomavirus infections, 409–410
for Kaposi's sarcoma, 381–382
for malignant melanoma, 385–387
for viral diseases, 380–381
in pediatric dermatology, 547–548
in scar revision, 184
Interleukins, for cutaneous T-cell lymphoma, 307–308
Intestinal obstruction, herpes simplex virus infections with, 785–786
Intralesional steroids, in scar revision, 184
Intravenous immune globulin, in pediatric dermatology, 581, 584, 588
Iontophoresis, for hyperhidrosis, 866–867
in transdermal drug delivery, 293–295
Iron, in dermatologic therapy, 637
Island pedicle flaps, in excision and repair, 68–69
Isolettes, to control transepidermal water loss, by neonatal skin, 443
Isotretinoin, adverse effects of, 336, 424–425
in pediatric dermatology. See *Retinoids.*
indications for, 333–335
Itraconazole, in pediatric dermatology, 530–532

Jarisch-Herxheimer reaction, in syphilis, 708

Jessner's solution, in chemical peels, 254

Kaposi's sarcoma, interferons for, 381–382
  radiotherapy for, 318
Kaposi's varicelliform eruption, in children, 544
Kasabach-Merritt phenomenon, birthmarks in, 458
Keloids, of ears, excision and repair of, 111
Keratinization, disorders of, acitretin and etretinate for, 332
Keratitis, herpetic, in children, 544
Keratoacanthoma, radiotherapy for, 317
Keratoconjunctivitis, herpetic, in children, 544
Keratoses, actinic, prevention of, sunscreens in, 222
Keratosis follicularis, retinoids for, in children, 563–564
Ketamine, in pediatric dermatology, 616
Khellin, plus UVA therapy, for vitiligo, 400–401
Klippel-Trenaunay syndrome, diagnostic imaging of, in children, 474–475
Krypton laser therapy, for vascular lesions, 255

Laboratory tests, before excision and repair, 10
  to screen for sexually transmitted diseases, 665
Lactobacilli, in bacterial vaginosis. See *Bacterial vaginosis.*
Lamellar ichthyosis, clinical features of, in children, 502–504
  retinoids for, in children, 557, 559
Lamivudine, for HIV infection, 413
Langer's lines, in simple excision and repair, 52
Laparoscopy, to diagnose pelvic inflammatory disease, 752–753
Laser matricectomy, technique for, 155–156
Laser therapy, for anogenital warts, 832
  for verrucae, of nails, 162
  preoperative evaluation for, 12–13
Laser vermilionectomy. See *Lips.*
Laser-modulating optics, advances in, 264
Lasers, advances in, **261–268**
    diode lasers, 263–264
    for hair removal, 256, 266–267
    for pigmented lesions, 256, 264–265
    for skin resurfacing, 254–255, 265–266
    for vascular lesions, 255–256, 264
    laser-modulating optics, 264
    non-laser devices, 264
    refinements to current lasers, 263
    selective photothermolysis, 261–263
      efficacy and adequacy of, 261–262
      photothermal sensitizers in, 263
      skin cooling in, 262–263
  future of, in diagnosis, 267
  in pediatric dermatology, **489–495**
    for pigmented lesions, 492–493
      café-au-lait macules, 492–493
      congenital melanocytic nevi, 493
      lentigines, 493
      nevus of Ota, 493
      nevus spilus, 493
    for vascular lesions, 489–492
      angiofibromas of tuberous sclerosis, 492
      port wine stains, 489–491
      pyogenic granulomas, 492
      telangiectasis, 491–492
    minimizing pain of, 614
  in scar revision, 183–184, 192–193
Latex allergy, and balanitis, 760
  and excision and repair, 6–7
Lathyrogenic agents, in scar revision, 184
Leg ulcers, wound healing in, 367–368
Leishmaniasis, and genital ulcers, 679–680
Lentigines, laser therapy for, in children, 493
Lentigo maligna, radiotherapy for, 317
Levamisole, for vitiligo, 403
Lice and scabies, **843–845**
  free-living, 844
  myths about, 844
  nonparasitic mites, 843
  parasitic mites, 843–844
Lichen planus, and balanitis, 760
  and genital ulcers, 681–682
  azathioprine for, 238
  in children. See *Adult skin disease.*
Lichen sclerosus et atrophicus, and balanitis, 761–762
  in children, 604–605
Ligase chain reaction, to diagnose nongonococcal urethritis, 724
Lipid disorders, acitretin and etretinate and, 425
Lipomas, as marker for spinal dysraphism, 451
Liposomal technology, in transdermal drug delivery, 292
Liposuction, preoperative evaluation for, 13
  tumescent, advances in, 256–257
Lips, excision and repair of, **127–142**
    anatomy in, 127–130
      blood supply, 128
      lip borders, 127–128
      motor innervation, 128–129
      muscles, 128
      sensory innervation, 130
    anesthesia in, 130–132
    carbon dioxide laser vermilionectomy, 140–142
      complications of, 142
      indications for, 141
      postoperative care for, 142
      technique for, 141–142
    Cupid's bow, 134
    full-thickness, 134–138
      indications for, 134–135
      postoperative care for, 136, 138
      technique for, 135–136
    partial-thickness, 132–134
      indications for, 132
      postoperative care for, 134
      technique for, 132–133
    vermilionectomy, 138–140
      complications of, 140
      indications for, 138
      postoperative care for, 140
      technique for, 138
Lobular defects, auricular, excision and repair of, 123
Local anesthetics, allergy to, and excision and repair, 6
Loracarbef, in pediatric dermatology, 515
Lumbosacral cutaneous lesions, as markers for spinal dysraphism, 450
Lumbosacral dimples, as markers for spinal dysraphism, 452
Lupus erythematosus, in children, 579–581
Lymph node involvement, by cutaneous T-cell lymphoma, 303–304
Lymphadenopathy, herpes simplex virus infections with, 785
Lymphatic malformations, diagnostic imaging of, in children, 474
Lymphatics, in simple excision and repair, 51
Lymphogranuloma venereum, and genital ulcers, 679
Lymphoma, cutaneous T-cell. See *Cutaneous T-cell lymphoma.*

Macrolides, in pediatric dermatology, 516–517
Maffucci syndrome, diagnostic imaging of, in children, 481
Magnetic resonance angiography, of birthmarks, 457
Magnetic resonance imaging, of birthmarks, 457
  of cranial dysraphism, 452
  of hemangiomas, 458
  of lymphatic malformations, 474
  of venous malformations, 472
Magnetic resonance venography, of birthmarks, 457
  of venous malformations, 472
Malignant melanoma, interferons for, 385–387
  prevention of, sunscreens in, 222–223
  PUVA photochemotherapy and, 228–229
  radiotherapy for, 317
  vaccines for, **269–275**
    clinical trials of, 273–274
    design strategies for, 271
    elements of, 270–271
    nonpurified, 272
    prepared from partially purified antigens, 273
    prepared from pure antigens, 272–273
    rationale for, 269–270
Mastocytosis, interferons for, 389
Matricectomy. See *Nails.*
Melanin deficiency, disorders of, in children, 573
Melanocyte grafts, autologous, for vitiligo, 404–405
Melanocytic nevi, laser therapy for, in children, 493
Meperidine, in pediatric dermatology, 615
Merkel cell carcinoma, radiotherapy for, 317–318
Metabolic complications, of systemic corticosteroids, 283
Methemoglobinemia, dapsone and, 423
Methicillin, in pediatric dermatology, resistance to, 511
Methotrexate. See *Immunosuppressive agents.*
Methylprednisolone, in pediatric dermatology, 584
Micropigmentation, for vitiligo, 405
Midazolam, in pediatric dermatology, 615
Midline forehead flaps, in nasal reconstruction, 106
Mineral waters, in dermatologic therapy, 632–633
Minocycline, adverse effects of, 422
  in pediatric dermatology, 519
Minoxidil, in hair regrowth, for alopecia areata, 351–352
    for androgenetic alopecia, 344–345, 347
Mohs micrographic surgery, for auricular defects, 112–113
  for nail defects, 158–159
  preoperative evaluation for, 13
Molecular diagnosis, of *Neisseria gonorrhoeae*, 714–715
Molluscum contagiosum, **839–841**
  AIDS and, 839–841
  histology of, 840
  historical aspects of, 839
  in children, 549
  recalcitrant, 840–841
  treatment of, 840
  virology of, 840
Mupirocin, in pediatric dermatology, resistance to, 511
Mycoplasmas, genital, in cervicitis, 741
    in nongonococcal nonchlamydial urethritis, 728
Mycosis fungoides, in children, 602–603
  radiotherapy for, 318–319

Nail involvement, by lichen planus, in children, 599, 600
  by psoriasis, in children, 594–595
Nail plate debridement, techniques for, 162–163
Nails, excision and repair of, **145–164**
    anatomy in, 145–147
    anesthesia in, 149–150
    biopsies in, 151–153
    blood supply in, 147
    dressings for, 150–151
    embryology in, 145
    for traumatic injuries, 159–161
      amputation or guillotine injuries, 161
      fractures, 161
      hematomas, 159–160
      lacerations, 160–161
    for verrucae, 161–162
      bleomycin, 162
      cryosurgery, 161–162
      electrosurgery, 162
      laser therapy, 162
    instrumentation for, 148
    matricectomy, 154–156
      carbon dioxide laser, 155–156
      chemical cautery, 156
      electrodesiccation and curettage, 155
      scalpel, 154–155
    Mohs micrographic surgery in, 158–159
    nail plate debridement, 162–163
    nerve supply in, 147
    paronychial surgery, 156–158
      en bloc excision of nail folds, 158
      excision of nail unit, 158
      excisional biopsy of nail folds, 156–157
      incisional biopsy of nail folds, 156
    postoperative care for, 150–151
    preoperative evaluation for, 147–148
    surgical avulsion, 153–154
Nasal gliomas, birthmarks as markers of, 448
Nasal reconstruction, **91–108**
  anatomy in, 91–92
  anesthesia in, 92–93
  composite grafts in, 97
  flaps in, 97–106
    for lateral sidewalls, 98–99
    for nasal ala, 101–104
    for nasal dorsum, 101
    for nasal root, 98
    for nasal tip, 104–106
  full-thickness skin grafts in, 95–97
  healing by secondary intention in, 94
  primary closure in, 94–95
  principles of, 93–94
  split-thickness skin grafts in, 95
Nasolabial flaps, in nasal reconstruction, 102–104
Neisseria gonorrhoeae, direct detection of, 714–715
Nelfinavir, for HIV infection, 415
Neonatal skin, **437–446**
  bathing of, 438–439
  cord care for, 439–443
  diapering of, 439
  emollients and diaper rash products for, 439
  injury to, 438
  percutaneous absorption by, 438
  transepidermal water loss by, control of, 443–445
Nerves, in simple excision and repair, 49–51
Neurosyphilis, HIV infection with, 700
  serology of, 695–696
  treatment of, 704–707
Nevi, of ears, excision and repair of, 111
Nevirapine, for HIV infection, 413–414
Nevoid basal cell carcinoma syndrome, retinoids for, in children, 566
Nevus of Ota, laser therapy for, in children, 493
Nevus spilus, laser therapy for, in children, 493
Nicotine, transdermal delivery of, 293

Nitroglycerin, transdermal delivery of, 292
Nocebo effect, in dermatologic therapy, 634
Nonbullous congenital ichthyosiform erythroderma, retinoids for, in children, 559
Nongonococcal nonchlamydial urethritis, **727–733**
acute, 727–729
chronic, 729–730
Mycoplasma genitalium in, 728
noninfectious causes of, 729
oral flora in, 729
Trichomonas vaginalis in, 728–729
Ureaplasma urealyticum in, 727–728
Nongonococcal urethritis, **723–726**
Chlamydia trachomatis negative, 725
Chlamydia trachomatis positive, 723–725
treatment of, 737
Non-nucleoside reverse transcriptase inhibitors, for HIV infection, 413–414
Nonsteroidal anti-inflammatory drugs, in pediatric dermatology, 588
N-Terface, in wound dressings, 41
Nutrition, and excision and repair, 6

O to T flaps, in excision and repair, of auricular defects, 115–116
O to Z flaps, in excision and repair, 69
Occlusive dressings, to control transepidermal water loss, by neonatal skin, 444
Ocular syphilis, HIV infection with, 700
treatment of, 707
Ophthalmic complications, of antimalarials, 422
of PUVA photochemotherapy, 229
of systemic corticosteroids, 283
Opportunistic infections, cyclophosphamide and, 241
methotrexate and, 244
Oral flora, in nongonococcal nonchlamydial urethritis, 729
Organ transplant, and excision and repair, 5
Osler-Weber-Rendu syndrome, diagnostic imaging of, in children, 481–483
Osteoporosis, systemic corticosteroids and, 280–281

Pain control, in children, **609–617**
age 7 to adult, 611–612
in infants, 610
in toddlers to age 6, 610–611
minimizing pain of cryotherapy, 613–614
minimizing pain of injections, 612–613
minimizing pain of pulsed dye laser, 614
nonpharmacologic, 609–610
pharmacologic, 614–616
Palmoplantar keratoderma, retinoids for, in children, 562
Parasitic diseases, in cervicitis, 743
Parkes-Weber syndrome, diagnostic imaging of, in children, 481
Paronychial surgery. See *Nails.*
Parotid gland, in simple excision and repair, 51
Partial-thickness excision, of lip defects. See *Lips.*
Partial-thickness skin grafts, in excision and repair. See *Skin grafts.*
in nasal reconstruction, 95–97
Partial-thickness wounds, healing of, 27
Parvovirus infection, in children, 549
Pearly penile papules, vs. human papillomavirus infections, 821
Pediatric dermatology, adult skin disease. See *Adult skin disease.*
antibiotics in. See *Antibiotics.*
antifungal agents in. See *Antifungal agents.*
antiviral agents in. See *Antiviral agents.*
birthmarks. See *Birthmarks.*
clinical psychology in. See *Clinical psychology.*
collagen vascular diseases. See *Collagen vascular diseases.*
inherited disorders of cornification. See *Inherited disorders of cornification.*
lasers in. See *Lasers.*
neonatal skin and skin care. See *Neonatal skin.*
pain control in. See *Pain control.*
photosensitivity disorders. See *Photosensitivity disorders.*
retinoids in. See *Retinoids.*
Pedicle flaps, in excision and repair, of auricular defects, 116–117
Pellagra, in children, 575
Pelvic inflammatory disease, 651–652, **747–756**
cervicitis and, 739
clinical features of, 749, 752
diagnosis of, 752–753
etiology of, 749
HIV infection with, 753–754
outcome of, 754
pathogenesis of, 748–749
prevention of, 754–755
recent trends in, 747–748
risk factors for, 747
treatment of, 753
Pemphigoid, azathioprine for, 238
Pemphigus, azathioprine for, 238
Penciclovir, for herpes simplex virus infections, 411
in pediatric dermatology, 542
Penicillamine, in pediatric dermatology, 586–587
Penicillin, for congenital syphilis, 707–708
for genital ulcers, due to syphilis, 677–678
for gonorrhea, 715
for neurosyphilis, 706
for syphilis, 702–703
in pediatric dermatology, 513
Peptic ulcer disease, systemic corticosteroids and, 282–283
Perioral dermatitis, rosacea and, in children, 600–601
PHACE syndrome, clinical features of, 461
Phenol, in chemical peels, 254
Phenylalanine, plus UVA therapy, for vitiligo, 401
Phlebology, advances in, 257
Phocomelia, thalidomide and, 424
Photoaging, pathogenesis of, 361–363
tretinoin for, **357–364**
for actinic dyspigmentation, 358
for fine wrinkles, 358, 360
for surface roughness, 358
irritation due to, 361
mechanism of action of, 360–361
Photochemotherapy, extracorporeal, in pediatric dermatology, 585
PUVA bath, in pediatric dermatology, 587
Photodermatoses, idiopathic, in children, 575–576
Photodynamic therapy, for cutaneous T-cell lymphoma, 305–306
in hair removal, 266
Photopheresis, plus interferons, for cutaneous T-cell lymphoma, 384
Photoprotection, in children, 576
Photosensitivity disorders, in children, **571–578**
disorders of cellular repair, 573–575

Photosensitivity disorders *(Continued)*
Bloom's syndrome, 574
Cockayne's syndrome, 574
Rothmund-Thomson syndrome, 574–575
xeroderma pigmentosum, 573–574
disorders of endogenous chromophore production, 572–573
disorders of tryptophan metabolism, 575
idiopathic photodermatoses, 575–576
melanin deficiency syndromes, 573
phototoxicity vs. photoallergy, 571–572
phytodermatitis, 572
protection from, 576
sunburn, 571–572
Photothermolysis, advances in, 261–263
Phototoxicity, tetracyclines and, in pediatric dermatology, 519
Physical medicine, in dermatologic therapy, 638–639
Phytodermatitis, in children, 572
Pigmented lesions, laser therapy for, 264–265
in children, 492–493
Pityriasis rubra pilaris, methotrexate for, 244
retinoids for, in children, 562–563
Placebo effect, in dermatologic therapy, 633–635
Plamapheresis, in pediatric dermatology, 587
Plasma cell balanitis, diagnosis of, 761
Plastic wraps, to control transepidermal water loss, by neonatal skin, 443–444
Podophyllin, for anogenital warts, 830
Podophyllotoxin, for anogenital warts, 830
Polidocanol, in sclerotherapy, 207
Polymer films, in wound dressings, 37–39
Polymer foams, in wound dressings, 39
Polymerase chain reaction test, for cutaneous T-cell lymphoma, 303
for neurosyphilis, 706–707
for nongonococcal nonchlamydial urethritis, 728
for nongonococcal urethritis, 724
for syphilis, 701–702
Polymorphous light eruption, in children, 575
Polymyxin B, in wound healing, 28, 29
Porphyrias, in children, 572–573
Port wine stains, laser therapy for, in children, 489–491
Povidone-iodine, in cord care, for neonatal skin, 441–442
Poxvirus infections, in children, 549
Prednisone, in pediatric dermatology, 583–584, 586, 587
Pregnancy, and excision and repair, 5–6
anogenital warts in, 832
genital herpes in. See *Genital herpes.*
herpes simplex virus infections in, 544–545
HIV infection in, 850–851
systemic corticosteroids during, 279
varicella in, 546
Pregnancy outcome, adverse, cervicitis and, 739
Premalignant skin lesions, acitretin and etretinate for, 332–333
Premature neonate, transdermal drug delivery in, 296
Promethazine, in pediatric dermatology, 615
Propranolol, as contraindication to excision and repair, 7
Prostaglandins, in scar revision, 184
Prostate, in chronic nongonococcal nonchlamydial urethritis, 730
Protease inhibitors, for HIV infection, 414–415
Proteus syndrome, diagnostic imaging of, in children, 475, 479
Protozoal diseases, and balanitis, 759
and cervicitis, 743
Pseudocatalase, plus calcium and UVB therapy, for vitiligo, 403
Pseudo-tails, as markers for spinal dysraphism, 452
Psoriasis, and balanitis, 760
in children. See *Adult skin disease.*
treatment of, 231–232
acitretin and etretinate in, 331
cyclosporine in, 246
Psoriasis vulgaris, interferons for, 389–390
Psychology, clinical. See *Clinical psychology.*
Pulsed dye laser therapy, in children, for café-au-lait macules, 493
for hemangiomas, 491
for port wine stains, 489–491
for pyogenic granulomas, 492
minimizing pain of, 614
Pulsed dye lasers, in scar revision, 183
Pulsed electromagnetic field, in dermatologic therapy, 638–639
Pustular psoriasis, in children, 595
PUVA photochemotherapy, **227–234**
benefits of, 230–231
for psoriasis, 231–232
for vitiligo, 399–400
historical aspects of, 231
in hair regrowth, for alopecia areata, 351
in pediatric dermatology, 587
risks of, 227–230
actinic degeneration, 227–228
immunologic changes, 229–230
ophthalmic effects, 229
skin cancer, 228–229
safety of, 232
Pyogenic granulomas, laser therapy for, in children, 492
Pyogenic skin infections, in children, antibiotics for, 520–521

Q-switched laser therapy, for café-au-lait macules, in children, 493
for nevus spilus, in children, 493
for pigmented lesions, 256
for vascular lesions, 255–256
Q-switched lasers, in hair removal, 256
Quinolones, in pediatric dermatology, 520

Radiation therapy, in scar revision, 184
Radiographs, of birthmarks, 457
of Klippel-Trenaunay syndrome, 474
of Maffucci syndrome, 481
Radiotherapy, for dermatologic malignancies, **313–320**
adverse effects of, 314–315
basal cell carcinoma, 316
cutaneous T-cell lymphoma, 318–319
Kaposi's sarcoma, 318
keratoacanthoma, 317
lentigo maligna, 317
malignant melanoma, 317
Merkel cell carcinoma, 317–318
modalities for, 313–314
factors influencing choice of, 315–316
squamous cell carcinoma, 316–317
techniques for, 314
Rapid plasmin reagin test, for syphilis, 701
Ratokderm, for vitiligo, 639–640
Raynaud's phenomenon, in children, 585–586
Rectal infections, herpes simplex virus infections with, 786
5α-Reductase, in hair regrowth, for androgenetic alopecia, 342–343

5α-Reductase inhibitors, in hair regrowth, for androgenetic alopecia, 343–344
Reiter's syndrome, and balanitis, 761
Relaxation techniques, in pediatric dermatology, 622–623
Renal complications, of cyclosporine, 245, 427
Reproductive complications, of cyclophosphamide, 241
of methotrexate, 244
Resting skin tension lines, in simple excision and repair, 52
Retinoids, for psoriasis, 232
in pediatric dermatology, **553–569**, 598
classification and pharmacokinetics of, 553–554
for Darier's disease, 563–564
for epidermodysplasia verruciformis, 566
for ichthyoses and ichthyosiform dermatoses, 557–562
collodion baby, 559–560
epidermolytic hyperkeratosis, 560–562
harlequin ichthyosis, 560
lamellar ichthyoses, 557, 559
nonbullous congenital ichthyosiform erythroderma, 559
for nevoid basal cell carcinoma syndrome, 566
for palmoplantar keratoderma, 562
for pityriasis rubra pilaris, 562–563
for psoriasis, 564–565
for xeroderma pigmentosum, 565–566
historical aspects of, 553
isotretinoin, 554–557, 581
dosing of, 554, 556
laboratory tests in, 557
nonresponse to, 556
relapse after, 556
side effects of, 556
with other acne medications, 556
side effects of, 566–567
plus interferons, for cutaneous T-cell lymphoma, 383–384
systemic. See *Systemic retinoids.*
Rheumatoid arthritis, in children, 587–589
Rhombic flaps, in excision and repair, 74
of auricular defects, 116
in nasal reconstruction, 101
Rintaula flaps, in nasal reconstruction, 105–106
Ritonavir, for HIV infection, 414
Rosacea, in children. See *Adult skin disease.*
Rotation flaps, in excision and repair. See *Flaps.*
in nasal reconstruction, 98–99, 101, 105
Rothmund-Thomson syndrome, in children, 574–575

Saquinavir, for HIV infection, 414
Scabies. See *Lice and scabies.*
Scalp reduction, in hair replacement, 257
Scalpel excision matricectomy, technique for, 154–155
Scar revision, **179–194**
color and, 181
contour and, 180–181
etiology and, 179–180
location and, 179
non-invasive, 181–185
camouflage techniques in, 185
compression in, 184
cryosurgery in, 184
electrocurrent in, 184
intralesional steroids in, 184
lasers in, 183–184
medications in, 184–185
radiation in, 184
silicone gel sheeting in, 181–182
soft tissue augmentation in, 182–183
patient expectations in, 179
shape and, 180
size and, 180
surgical, 185–193
extramarginal excision in, 185–186
intramarginal excision in, 186–187
lasers in, 192–193
spot dermabrasion in, 191–192
V-Y advancement flap in, 191
W-plasty in, 187–188
Z-plasty in, 187–191
Scars, congenital, as markers for spinal dysraphism, 452
Scissor excision, for anogenital warts, 831
Scleroderma, in children, 585–587
interferons for, 390
Sclerotherapy, **195–211**
activity after, 207–208
documentation in, 203
ectasia classification in, 200–201
for venous malformations, 469, 472
initial treatment in, 203
instrumentation for, 206–207
minimizing complications of, 208–210
patient evaluation for, 13, 201–203
history in, 201
noninvasive vascular tests in, 202
patient education in, 202
physical examination in, 201–202
treatment plan in, 202–203
patient preparation for, 203
technique for, 203–206
concentration of injectate, 204
empty vein technique, 204
intravascular injection, 204
postsclerotherapy compression, 204–206
vein cannulation, 204
volume of injectate, 204
venous system anatomy in, 195, 200
venous system hemodynamics in, 200
Scopolamine, transdermal delivery of, 292
Scratching behavior, in children, 623–624
Sebosuppression, systemic retinoids in, 333–334
Seizure disorders, and excision and repair, 6
Selenium, in dermatologic therapy, 638
Serologic tests, to screen for sexually transmitted diseases, 665
Seromas, ear surgery and, 124
full-thickness skin grafts and, 81
Sexually transmitted diseases, AIDS. See *AIDS.*
bacterial vaginosis. See *Bacterial vaginosis.*
balanitis. See *Balanitis.*
cervicitis. See *Cervicitis.*
clinical treatment of, 656
etiologic treatment of, 656
future trends in, 650
genital herpes. See *Genital herpes.*
genital pain syndrome. See *Genital pain syndrome.*
genital ulcers, 651
gonorrhea. See *Gonorrhea.*
herpes simplex virus infections. See *Herpes simplex virus infections.*
historical aspects of, 649–650
HIV infection. See *HIV infection.*
human papillomavirus infections. See *Human papillomavirus infections.*
in children, **859–861**
differentiation due localization of infection, 860

Sexually transmitted diseases *(Continued)*
differentiation due to age of child, 859
differentiation due to transmittable agent, 859–860
in women, 656
international control of, need for, 657
lice and scabies. See *Lice and scabies.*
models of care for, 653–654
molluscum contagiosum. See *Molluscum contagiosum.*
nongonococcal nonchlamydial urethritis. See *Nongonococcal nonchlamydial urethritis.*
nongonococcal urethritis. See *Nongonococcal urethritis.*
partner notification techniques for, **669–672**
diseases selected for, 670
enhancement of, 672
interview in, 670
limitations of, 671
methods for, 670
rationale for, 669
setting in, 669–670
tools for, 670–671
pelvic inflammatory disease. See *Pelvic inflammatory disease.*
physician training in, 657–658
resurgence of, in Russian and Eastern Europe, **659–662**
anonymous testing and treatment for, 661–662
guidelines for managing, 661
reasons for, 660–661
screening for, **663–667**
in risk groups, 663–664
laboratory tests in, 665
methodologies for, 665–666
principles of, 666
procedures for, 664–665
syndromic treatment of, 656–657
syphilis. See *Syphilis.*
urethritis, 651–652
vaginitis, 652
vulvodynia. See *Vulvodynia.*
vulvovaginitis. See *Vulvovaginitis.*
Silicone, in scar revision, 182–183
Silicone gel sheeting, in scar revision, 181–182
Sjögren's syndrome, in children, 589
Skin cancer, prevention of, sunscreens in, 222
PUVA photochemotherapy and, 228–229
Skin grafts, in excision and repair, **75–90**
and wound healing, 75–77
composite, 86–88
and wound healing, 86
auricular, 86–87
donor site closure in, 88
technique for, 87–88
free cartilage, 88
full-thickness, 77–82
complications of, 81–82
donor site in, 77–79
indications for, 77
securing, 79–81
technique for, 79
of auricular defects, 117, 119
split-thickness, 82–86
complications of, 85–86
donor site care in, 85
donor site in, 82, 84
indications for, 82
securing, 84–85
technique for, 84
in nasal reconstruction, 95–97
Skin resurfacing, lasers in, 254–255, 265–266
preoperative evaluation for, 13
Skin substitutes, in wound healing, 371
Skin tumors, epithelial, interferons for, 387–389
Skin-directed therapy, for cutaneous T-cell lymphoma, 305–306
Sleep disorders, and excision and repair, 6
in pediatric dermatology, 624–625
Smoking, and excision and repair, 8
Sodium morrhuate, in sclerotherpay, 207
Sodium tetradecyl sulfate, in sclerotherapy, 207
Soft tissue augmentation, in scar revision, 182–183
Sorivudine, for herpes simplex virus infections, 412
Southern blotting, in cutaneous T-cell lymphoma, 304
Spinal dysraphism, birthmarks as markers of. See *Birthmarks.*
Spironolactone, in hair regrowth, for androgenetic alopecia, 344
Splinter hemorrhages, of nails, 159
Split-thickness skin grafts, in excision and repair, of auricular defects, 119
in nasal reconstruction, 95
Spot dermabrasion, in scar revision, 191–192
Squamous cell carcinoma, and balanitis, 761–762
genital, ulcerated, 682
interferons for, 388
radiotherapy for, 316–317
Squaric acid dibutyl ester, in hair regrowth, for alopecia areata, 350–351
Staphylococcus aureus, resistance of, to antibiotics, 510–511
Stavudine, for HIV infection, 413
Steroid-metabolizing enzymes, in hair regrowth, for androgenetic alopecia, 342–343
Steroids, in pediatric dermatology, 580, 583, 588–589, 596–597, 600
intralesional, in scar revision, 184
Streptococcus pyogenes, resistance of, to antibiotics, 510
Sturge-Weber syndrome, diagnostic imaging of, in children, 483
Subacute cutaneous lupus erythematosus, interferons for, 389
Subungual hematomas, management of, 159–160
Sulfasalazine, in pediatric dermatology, 588
Sulfur-containing amino acids, in dermatologic therapy, 638
Sunburn, in children, 571–572
Sunscreens, **219–226**
application rate of, 220
in elderly, 221
photodegradation of, 221–222
rationale for, 222–223
skin reactions to, 221
sun protective factor in, 220–221
to reduce immunosuppression, from ultraviolet light, 223–224
Surgical tray, in excision and repair, **17–24**
curettes, 21
forceps, 19–20
hemostats, 21
instrument care for, 22
needle holders, 20–21
scalpels and blades, 17–18
scissors, 18–19
skin hooks, 21
sterilization of, 22–23
Sutured wounds, healing of, 27
Sweet's syndrome, in children, 602
Sympathectomy, for hyperhidrosis, 865–866
Syphilis, 650–651
and balanitis, 759
and genital ulcers, 677–678

HIV infection with, 854
in Russia, **687–690**
acquired, in children, 687
congenital, 687
malignant, 690
laboratory tests for, 701–702
resurgence of, in Russian and Eastern Europe, 660–661
serology of, **691–698**
and response to treatment, 694
at different stages, 692–694
late or latent, 693
primary, 692
secondary and early latent, 693
treated, 693
confirmatory tests in, 695
congenital syphilis, 696
neurosyphilis, 695–696
Treponema pallidum detection in, 696–697
treponemal antigen tests in, 694–695
treatment of, **699–711**
azithromycin in, 703–704
ceftriaxone in, 703
congenital syphilis, 707–708
doxycycline in, 704
HIV infection with, 699–701
Jarisch-Herxheimer reaction in, 708
neurosyphilis, 704–707
ocular and cardiovascular syphilis, 707
penicillin in, 702–703
registration and partner notification in, 709
Systemic corticosteroids, **277–288**
complications of, 280–283
cardiovascular, 283
central nervous system, 283
connective tissue, 280–282
gastrointestinal, 282–283
in children, 283
infections, 282
malignancies, 283–284
metabolic, 283
ophthalmic, 283
dosing schedules for, 277–278
drug interactions with, 279
elimination of, factors affecting, 278
hypothalamic pituitary adrenal axis effects of, 279–280
in breastfeeding, 279
in pregnancy, 279
medicolegal implications of, 284–285
patient monitoring for, 284
sample consent form for, 287–288
Systemic retinoids, **331–340**
acitretin and etretinate, 331–333, 336
adverse effects of, 335–336
"cross-talk," 338
dissociating, 337
isotretinoin, 333–336
receptor subtype-selective, 337
tretinoin, 335

Tails, as markers for spinal dysraphism, 452
Targretin, for cutaneous T-cell lymphoma, 306
Tattooing, for vitiligo, 405
Tazarotene, in pediatric dermatology, 597
Telangiectasis, as marker for spinal dysraphism, 451
laser therapy for, in children, 491–492
Telangiectatic capillaries, sclerotherapy for. See *Sclerotherapy.*
Telangiectatic capillary matting, sclerotherapy and, 208–209
Telangiectatic veins, sclerotherapy for. See *Sclerotherapy.*
Telfa, in wound dressings, 41
Teratogenicity, of acitretin and etretinate, 425
Terbinafine, in pediatric dermatology, 533–535
Testosterone, transdermal delivery of, 293
Tethered cord syndrome, birthmarks as markers of, 450
Tetracyclines, adverse effects of, 421–422
in pediatric dermatology, 517–520
Thalidomide, adverse effects of, 423–424
Tissue remodeling, in excision and repair, 26–27
Topical anesthetics, allergy to, and excision and repair, 6
Tragal defects, excision and repair of, 122–123
Transarterial angiography, of birthmarks, 457
Transdermal drug delivery, **289–299**
biologic barrier in, 289–290
blood chemistry monitoring in, 295
evaluating barrier function in, 295–296
future of, 296–297
in premature neonate, 296
indications for, 291–293
iontophoresis in, 293–295
stratum corneum function and, 290
suitability of compounds for, 290–291
Transepidermal water loss, by neonatal skin, 437–438
control of, 443–445
Transposition flaps, in excision and repair. See *Flaps.*
in nasal reconstruction, 98, 101, 102–104
Trauma, to nails. See *Nails.*
Treponema pallidum, in syphilis, direct detection of, 696–697
Treponemal antigen tests, for neurosyphilis, 705–706
for syphilis, 694–695, 701
Tretinoin, in scar revision, 184–185
indications for, 335
hair regrowth, for androgenetic alopecia, 347
photoaging. See *Photoaging.*
Trichloroacetic acid, for anogenital warts, 830–831
in chemical peels, 254
Trichomonas vaginalis, in balanitis, 759
in nongonococcal nonchlamydial urethritis, 728–729
Triple dye, in cord care, for neonatal skin, 440–441
Tryptophan metabolism, disorders of, in children, 575
Tuberculosis, and balanitis, 759
and cervicitis, 743
Tuberous sclerosis, angiofibromas of, laser therapy for, in children, 492
Tumescent liposuction, advances in, 256–257
Tumors, epithelial skin, interferons for, 387–389
genital, ulcerated, 682
malignant, of ears, excision and repair of, 112

Ulcers, genital. See *Genital ulcers.*
leg, wound healing in, 367–368
Ultrapulse laser therapy, for verrucae, of nails, 162
Ultrasonic liposuction, advances in, 256–257
Ultrasonography, of birthmarks, 457
of hemangiomas, 458
Ultraviolet light, in pediatric dermatology, 597
Ureaplasma urealyticum, in nongonococcal nonchlamydial urethritis, 727–728
Urethritis, 651–652
gonococcal, treatment of, 736–737
nongonococcal. See *Nongonococcal urethritis.*
nongonococcal nonchlamydial. See *Nongonococcal nonchlamydial urethritis.*
Urinary retention, herpes simplex virus infections with, 785

Urologic complications, of cyclophosphamide, 241
Urticaria, herpes simplex virus infections with, 786
UVA therapy, for vitiligo, 400–401
UVB therapy, for psoriasis, 231
  for vitiligo, 403

Vaginitis, definition of, 652
Vaginosis, bacterial. See *Bacterial vaginosis.*
Valacyclovir, for herpes simplex virus infections, 411–412
  in pediatric dermatology, 542, 543
Varicella, in children, 545–546
Varicella-zoster infections, in children, 539–540, 542
Varicose veins, sclerotherapy for. See *Sclerotherapy.*
Variegate porphyria, in children, 573
Vascular lesions, laser therapy for, 264
Vasculature, in simple excision and repair, 49
VDRL test, for syphilis, 701
Venography, of birthmarks, 457
Venous malformations, diagnostic imaging of, in children, 468–469, 472
Vermilionectomy. See *Lips.*
Verrucae, of nails. See *Nails.*
Vestibular papillomatosis, vs. human papillomavirus infections, 820
Vestibulitis, vulval, 776–777
Viral diseases, **409–420**
  and balanitis, 759
  herpes simplex virus infections. See *Herpes simplex virus infections.*
  HIV infection. See *HIV infection.*
  human papillomavirus infections. See *Human papillomavirus infections.*
  in children, child abuse and, 549–550
  interferons for, 380–381
Vitamin A analogs, indications for, 332
Vitiligo, **399–407**
  medical treatment of, 399–403
    corticosteroids in, 401–403
    khellin and UVA therapy in, 400–401
    phenylalanine and UVA therapy in, 401
    pseudocatalase and calcium with UVB therapy in, 403
    PUVA photochemotherapy in, 399–400
  Ratokderm for, 639–640
  surgical treatment of, 403–405
    autologous epidermal grafts in, 403–404
    autologous melanocyte grafts in, 404–405
Vulvodynia, **775–778**
  dysesthetic, 776
  future trends in, 777–778
  historical aspects of, 775
  related to infection and dermatoses, 775–776
  vulval vestibulitis, 776–777
Vulvovaginitis, **763–768**
  azole-resistant, 765
  diagnosis of, 763–764
    yeast cultures in, 764–765
  etiology of, 764
  herpetic, in children, 542–544
  non-*albicans*, 765–766
  recurrent, 766–767
V-Y advancement flaps, in scar revision, 191

Wedge excision, of auricular defects, 119–120
Western blot assay, for genital herpes, 791
Whitlow, herpetic, in children, 544
Wound contraction, in excision and repair, 26–27
Wound healing, **365–375**
  in excision and repair, dressings and. See *Dressings.*
    skin grafts and, 75–77, 86
  of acute wounds, 365–366
  of chronic wounds, 366–372
    accurate diagnosis in, 366–367
    based on etiology, 367–368
    based on symptoms, 368–372
      autolysis, 368
      biosurgery, 369
      cleansing, 368
      debridement, 368
      dressings, 369–371
      enzymatic debridement, 369
      growth factors, 372
      mechanical debridement, 368–369
      osmotic debridement, 369
      pharmacologic therapy, 371–372
      surgery, 371
      surgical debridement, 368
  of incurable wounds, 374
  of infected acute wounds, 366
  of infected or colonized chronic wounds, 372–374
Wound infections, after simple excision and repair, 63
    prevention of, 31–33
Wounds, categories of, 31
W-plasty, in scar revision, 187–188

Xeroderma pigmentosum, in children, 573–574
    retinoids for, 565–566
Xerodressings, in wound healing, 370
X-linked recessive ichthyosis, clinical features of, 499–500

Yeast infections, vs. human papillomavirus infections, 820

Zalcitabine, for HIV infection, 413
Zidovudine, for HIV infection, 412–413
Zinc, in dermatologic therapy, 637–638
Z-plasty, in scar revision, 188–191